Follow The Filings

BCYC Bicycle Therapeutics

Bicycle Therapeutics earnings company data as of 6:58 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 29 Oct EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by BCYC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BCYC insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $17K sold by 2 insiders under 10b5-1 plans
  1. Jennifer Scott Perry COO
    Planned sale
    $1,232 326 shares at $3.78 0.4% of stake
    Traded Oct 5 Filed Oct 7
  2. Jennifer Scott Perry COO
    Planned sale
    $1,445 333 shares at $4.34 0.4% of stake
    Traded Jul 6 Filed Jul 7
  3. Jennifer Scott Perry COO
    Planned sale
    $1,678 333 shares at $5.04 0.4% of stake
    Traded Apr 6 Filed Apr 6
  4. Alethia Young CFO
    Planned sale
    $12K 1,878 shares at $6.54 2.1% of stake
    Traded Jan 5 Filed Jan 6

Also filed in the last 12 months, not counted as buying or selling: 43 sales to cover taxes and 16 stock grants.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 5.02
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.07
8-K 8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
8-K 8.01,9.01
8-K 2.02,5.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.